Jaguar Health reported a sharp 816% year-over-year revenue increase to $20.27 million in Q1 2026, driven mainly by a licensing deal for its U.S. commercial rights to Mytesi and Canalevia-CA1. Despite this revenue surge, the company remains unprofitable with a net loss of $7.02 million, though this is an improvement from the previous year's $10.46 million loss. Jaguar is shifting focus toward developing crofelemer for rare intestinal diseases while facing financial challenges such as weak liquidity and negative equity. Upcoming presentations on crofelemer for rare pediatric intestinal conditions are planned for June 2026.
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
